MALVERN, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the following investor conferences in March.
Cowen and Company 38th Annual Health Care Conference
Location: Marriott Copley Place, Boston
Date / Time: Tuesday, March 13, at 11 a.m. EDT
Needham & Company 17th Annual Healthcare Conference
Location: Westin New York Grand Central, New York City
Date / Time: Tuesday, March 27, at 9:30 a.m. EDT
About PhaseBio
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases. PhaseBio is leveraging its proprietary elastin-like polypeptide (ELP) biopolymer technology platform to develop therapies with the potential for less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension. The company is also developing PB2452, a reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098
lbagby@6degreespr.com